TITLE:
Clinical Significance of Topical Spermidine Hyaluronate in Vestibulodynia: An Early Appraisal
AUTHORS:
Filippo Murina, Carlo Ghisalberti
KEYWORDS:
Vestibulodynia, Spermidine, Vulvodynia, Dyspareunia, Vulvar Pain
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.13 No.12,
December
28,
2023
ABSTRACT: Background: The most common subtype of chronic vulvar pain is provoked vestibulodynia. The entry of the vagina is
the site of acute and recurrent pain in this highly prevalent and debilitating condition, which is characterized
by pressure application or
attempted vaginal penetration. The aim of this study was to determine the effectiveness of topical spermidine in
patients with vestibulodynia. Methods: Topical gels containing
spermidine in hyaluronate complexes Ubi1 and Ubi2 endowed with
differentiated release ratio and viscosity were applied at 3 doses/week during
4-weeks, then at 2 doses/week during the
next 4-weeks in two groups of patients. Pain relief was measured by visual
analogic score (VAS) and dyspareunia score expressed as percent
improvement from baseline to posttreatment. Results: Group 1 treated
with Ubi1 provided improvement in pain (46%)
and dyspareunia (27%). However, the treatment in Group 2 resulted in a superior amelioration: VAS of
pain (76%) and dyspareunia (50%) as
Ubi2 gel provided higher dose and viscosity along with improved local
application. Conclusions: Our results demonstrated that preparation 2
resulted in greater reduction in symptoms as compared to preparation 1 as measured
by the VAS and Marinoff scale. These early, yet outstanding clinical outcomes
in vestibulodynia through to the stimulation of tissue mechanosensor and their relevant downstream effects are reviewed
hereafter.